Search Results
494 items found for "Bcl-2"
- Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases
September 2022 "Glutamate is the primary excitatory neurotransmitter in the brain and plays critical
- Functional Characterization of the Venus Flytrap Domain of the Human TAS1R2 Sweet Taste Receptor
September 2022 "The human sweet taste receptor is a heterodimeric receptor composed of two distinct G-protein-coupled
- Dynamic recognition of naloxone, morphine and endomorphin1 in the same pocket of µ-opioid receptors
September 2022 "Morphine, the most widely used analgesic, relieves severe pain by activating the
- Isoform-and ligand-specific modulation of adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder
September 2022 "Adhesion G protein-coupled receptors (aGPCRs) are cell-surface proteins with large extracellular
- Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota..
September 2022 Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism
- Endocannabinoid System in the Neuroendocrine Response to Lipopolysaccharide-induced Immune Challenge
September 2022 "The endocannabinoid system plays a key role in the intersection of the nervous, endocrine
- Arginine 125 Is an Essential Residue for the Function of MRAP2
September 2022 "MRAP2 is a small simple transmembrane protein arranged in a double antiparallel topology
- Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of...
September 2022 Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model
- Endogenous ligand recognition and structural transition of a human PTH receptor
September 2022 "Endogenous parathyroid hormone (PTH) and PTH-related peptide (PTHrP) bind to the parathyroid structures of six forms of the human PTH1R-Gs complex in the presence of PTH or PTHrP at resolutions of 2.8
- Trainees, this is for you...
GPCR Summit 2022. Mark your calendar for October 10th and 16th.
- Join Us Now!
GPCR Summit 2022. This is a great opportunity for us to come together and talk GPCRs. Join us now ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-summit-2022 #gpcr #drgpcr
- Addex Raises $10 Million In Equity Financing
December 2021 "Geneva, Switzerland, December 17, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq
- Carola Weiss joins InterAx Biotech AG as VP Business Development
February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical
- Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr.
- Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline ...
January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven The companies have been working together since 2016 and in 2019, Sanofi in-licensed Exscientia ’s novel
- Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain
December 2021 "3-part randomized, double-blind, placebo-controlled Phase 1 study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start in early Q1 2022 CHESTERBROOK , Pa., Dec. 13, 2021 - Trevena , Inc.
- Oxford Professor Of Chemistry And Founder Of Therapeutic Company Wins Two International Awards
December 2021 " Dame Carol Robinson DBE, FRS, FRSC, FMedSci, Oxford University’s first female Professor ongoing consultant to) OMass Therapeutics , which is based at Oxford Science Park, has been awarded the 2022
- Sosei Heptares Announces Antitrust Clearance of License Agreement with Neurocrine Biosciences
December 2021 " Tokyo, Japan and Cambridge, UK, 24 December 2021 – Sosei Group Corporation (“ Sosei Agreement (“License Agreement”) with Neurocrine Biosciences , Inc. (“ Neurocrine Biosciences ”) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) expired on 22 December 2021. As such, the License Agreement became effective on 22 December 2021.
- Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research
December 2021 "Meet Peter McNamara , Ph.D., Tectonic ’s SVP, Head of Research.
- Professor Charlotte Deane Joins Exscientia as Chief Scientist of Biologics AI
January 2022 "OXFORD, England--Professor Charlotte Deane , Ph.D., of the University of Oxford , has
- Verily links up with Sosei Heptares for GPCR drug discovery
January 2022 "G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers in GPCR-based drug discovery have clocked in at $1 billion—with Genentech—and, just last November, $2.6
- Learn more about Neurocrine Biosciences with their new video
January 2022 "The Neurocrine Biosciences story puts into words what makes the work and people at
- ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated ...
January 2022 ChemoCentryx Announces EU Approval of TAVNEOS® (avacopan) for the Treatment of ANCA-Associated Vasculitis "SAN CARLOS, Calif., Jan. 19, 2022, today announced that TAVNEOS® (avacopan) has been approved Food and Drug Administration (FDA) approval of TAVNEOS in October 2021.
- Novo Nordisk moves to strengthen obesity efforts
January 2022 "After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position
- Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
February 2022 Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder "J an 27, 2022 07:00am Septerna wants to spark a second golden age in G-protein-coupled
- InterAx Biotech AG and Boehringer Ingelheim take collaborate to unlock orphan targets leveraging ...
February 2022 " InterAx Biotech AG and Boehringer Ingelheim take first steps towards collaborating
- Ermium Therapeutics has constituted its SAB
February 2022 " Ermium Therapeutics Announces the Formation of a Scientific Advisory Board comprising
- Research Network on Signal Transduction (ERNEST) has established an Emergency Fund for Ukrainian ...
March 2022 ERNEST has established an Emergency Fund for Ukrainian researchers. institutions, or private companies) Deadlines Start of the project: now End of the project: 31 October 2022